{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:48:20Z","timestamp":1794473300981,"version":"4.9.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.coviro.2022.101204","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T19:23:21Z","timestamp":1644434601000},"page":"101204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0747-7760","authenticated-orcid":false,"given":"Guilherme Dias","family":"de Melo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0458-7916","authenticated-orcid":false,"given":"Jan","family":"Hellert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3307-6541","authenticated-orcid":false,"given":"Rajesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bourhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2022.101204_bib0005","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.coviro.2022.101204_bib0010","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0015","series-title":"World Health Organization Expert Consultation on Rabies, Third Report: WHO Technical Report Series 1012","author":"WHO","year":"2018"},{"key":"10.1016\/j.coviro.2022.101204_bib0020","series-title":"2019 release","author":"Virus Taxonomy","year":"2019"},{"key":"10.1016\/j.coviro.2022.101204_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/v13010069","article-title":"Genetic and antigenetic characterization of the novel Kotalahti bat lyssavirus (KBLV)","volume":"13","author":"Calvelage","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2022.101204_bib0030","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/JVI.75.7.3268-3276.2001","article-title":"Evidence of two lyssavirus phylogroups with distinct pathogenicity and immunogenicity","volume":"75","author":"Badrane","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101204_bib0035","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/v11100892","article-title":"Current rabies vaccines do not confer protective immunity against divergent lyssaviruses circulating in Europe","volume":"11","author":"Echevarr\u00eda","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2022.101204_bib0040","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3201\/eid2404.171696","article-title":"Lyssavirus in Japanese pipistrelle, Taiwan","volume":"24","author":"Hu","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/QCO.0000000000000420","article-title":"Rabies: changing prophylaxis and new insights in pathophysiology","volume":"31","author":"Ugolini","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0050","first-page":"315","article-title":"The acetylcholine receptor as a cellular receptor for rabies virus","volume":"56","author":"Lentz","year":"1983","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.coviro.2022.101204_bib0055","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1128\/JVI.72.9.7181-7190.1998","article-title":"The neural cell adhesion molecule is a receptor for rabies virus","volume":"72","author":"Thoulouze","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101204_bib0060","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1093\/emboj\/17.24.7250","article-title":"Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus","volume":"17","author":"Tuffereau","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.coviro.2022.101204_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007189","article-title":"Metabotropic glutamate receptor subtype 2 is a cellular receptor for rabies virus","volume":"14","author":"Wang","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2022.101204_bib0070","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/infdis\/jiy081","article-title":"The role of heparan sulfate proteoglycans as an attachment factor for rabies virus entry and infection","volume":"217","author":"Sasaki","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0075","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01819-19","article-title":"Integrin beta1 promotes peripheral entry by rabies virus","volume":"94","author":"Shuai","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101204_bib0080","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1474-4422(13)70038-3","article-title":"Human rabies: neuropathogenesis, diagnosis, and management","volume":"12","author":"Hemachudha","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coviro.2022.101204_bib0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.20506\/rst.37.2.2825","article-title":"Rabies: a medical perspective","volume":"37","author":"Jackson","year":"2018","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.coviro.2022.101204_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006041","article-title":"Large-scale phylogenomic analysis reveals the complex evolutionary history of rabies virus in multiple carnivore hosts","volume":"12","author":"Troupin","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2022.101204_bib0095","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2022.101204_sbref0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.chom.2019.12.012","article-title":"Structural analysis of rabies virus glycoprotein reveals pH-dependent conformational changes and interactions with a neutralizing antibody","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2022.101204_bib0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1135710","article-title":"Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G","volume":"315","author":"Roche","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101204_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004756","article-title":"Structure of the low pH conformation of Chandipura virus G reveals important features in the evolution of the vesiculovirus glycoprotein","volume":"11","author":"Baquero","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2022.101204_bib0115","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nsmb.1484","article-title":"The postfusion structure of baculovirus gp64 supports a unified view of viral fusion machines","volume":"15","author":"Kadlec","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coviro.2022.101204_bib0120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc1726","article-title":"The prefusion structure of herpes simplex virus glycoprotein B","volume":"6","author":"Vollmer","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2022.101204_bib0125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0042-6822(92)90465-2","article-title":"Rabies virus glycoprotein is a trimer","volume":"187","author":"Gaudin","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2022.101204_bib0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4172\/jaa.1000061","article-title":"Conservation of binding epitopes for monoclonal antibodies on the rabies virus glycoprotein","volume":"5","author":"Kuzmina","year":"2013","journal-title":"J Antivirals Antiretrovirals"},{"key":"10.1016\/j.coviro.2022.101204_bib0135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.15252\/emmm.201505986","article-title":"Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis","volume":"8","author":"De Benedictis","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.coviro.2022.101204_sbref0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14398-7","article-title":"Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein","volume":"11","author":"Hellert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101204_bib0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006133","article-title":"SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies","volume":"11","author":"Chao","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0150","article-title":"A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis","volume":"16","author":"Kim","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2022.101204_bib0155","first-page":"593","article-title":"Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons","volume":"14","author":"Atanasiu","year":"1956","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coviro.2022.101204_bib0160","first-page":"911","article-title":"Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. II","volume":"17","author":"Atanasiu","year":"1957","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coviro.2022.101204_bib0165","first-page":"103","article-title":"Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 3","volume":"25","author":"Atanasiu","year":"1961","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coviro.2022.101204_bib0170","first-page":"361","article-title":"Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 4","volume":"36","author":"Atanasiu","year":"1967","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coviro.2022.101204_bib0175","first-page":"163","article-title":"Results of rabies post-exposure treatment with antirabies serum and the human diploid cell vaccine in Iran","volume":"40","author":"Bahmanyar","year":"1978","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.coviro.2022.101204_bib0180","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1001\/jama.1976.03270250019017","article-title":"Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum","volume":"236","author":"Bahmanyar","year":"1976","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2022.101204_bib0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1580\/1080-6032(2000)011[0042:PTWTNH]2.3.CO;2","article-title":"Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum","volume":"11","author":"Bahmanyar","year":"2000","journal-title":"Wildern Environ Med"},{"key":"10.1016\/j.coviro.2022.101204_bib0190","first-page":"168","article-title":"The use of antirabies gamma globulin in subjects severely bitten by rabid wolves or other animals","volume":"3","author":"Selimov","year":"1959","journal-title":"J Hyg Epidemiol Microbiol Immunol"},{"key":"10.1016\/j.coviro.2022.101204_bib0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1051\/jbio\/2009049","article-title":"The use of passive rabies immunotherapy: from the past to the future","volume":"204","author":"Bourhy","year":"2010","journal-title":"Biol Aujourdhui"},{"key":"10.1016\/j.coviro.2022.101204_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000243","article-title":"Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab\u2019)(2) fragment rabies immunoglobulin (Favirab)","volume":"2","author":"Quiambao","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2022.101204_sbref0205","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.vaccine.2019.04.024","article-title":"Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017\u20132018","volume":"37","author":"Sreenivasan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2022.101204_bib0210","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018 - recommendations","volume":"36","author":"WHO","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2022.101204_bib0215","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nbt1135","article-title":"Human antibodies from transgenic animals","volume":"23","author":"Lonberg","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2022.101204_bib0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF03259250","article-title":"Monoclonal antibodies in rabies therapy","volume":"1","author":"Dietzschold","year":"1994","journal-title":"Clin Immunother"},{"key":"10.1016\/j.coviro.2022.101204_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1134\/S0006297918010017","article-title":"Recombinant monoclonal antibodies for rabies post-exposure prophylaxis","volume":"83","author":"Ilina","year":"2018","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.coviro.2022.101204_bib0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.coviro.2022.101204_bib0235","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coche.2018.01.007","article-title":"Engineering therapeutic antibodies to combat infectious diseases","volume":"19","author":"Wagner","year":"2018","journal-title":"Curr Opin Chem Eng"},{"key":"10.1016\/j.coviro.2022.101204_sbref0240","doi-asserted-by":"crossref","first-page":"A73","DOI":"10.1016\/j.vaccine.2018.10.012","article-title":"Global characteristics of the rabies biologics market in 2017","volume":"37","author":"Ives","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2022.101204_bib0245","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0250","volume":"vol 2021","year":"2021"},{"key":"10.1016\/j.coviro.2022.101204_bib0255","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.coviro.2022.101204_sbref0260","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline","volume":"37","author":"Sparrow","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2022.101204_bib0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.antiviral.2011.06.002","article-title":"G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates","volume":"91","author":"Wang","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2022.101204_bib0270","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1080\/22221751.2019.1683436","article-title":"Antigenic variations of recent street rabies virus","volume":"8","author":"Wang","year":"2019","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.coviro.2022.101204_bib0275","volume":"vol 2021","year":"2021"},{"key":"10.1016\/j.coviro.2022.101204_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/df98339d-6bdb-40ed-af83-cc38b249264a","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0285","series-title":"A Phase 3, Randomised, Open-label, Non-inferiority Trial Evaluating Anti-rabies Monoclonal Antibody Cocktail (Twinrab TM) Against Human Rabies Immunoglobulin (HRIG)","author":"Kansagra","year":"2019"},{"key":"10.1016\/j.coviro.2022.101204_bib0290","article-title":"In vivo efficacy of SYN023, an anti-rabies monoclonal antibody cocktail, in post-exposure prophylaxis animal models","volume":"5","author":"Chao","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104956","article-title":"Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: an open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects","volume":"184","author":"Ding","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2022.101204_sbref0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpdd.917","article-title":"Safety, pharmacokinetics, and neutralizing activity of SYN023, a mixture of two novel antirabies monoclonal antibodies intended for use in postrabies exposure prophylaxis","volume":"10","author":"McClain","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.coviro.2022.101204_bib0305","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.vaccine.2021.08.066","article-title":"Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: results of a phase 2, randomized, blinded, controlled trial","volume":"39","author":"McClain","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2022.101204_bib0310","series-title":"A Phase III Clinical Study to Evaluate SYN023\u2019s Efficacy and Safety","author":"ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.coviro.2022.101204_bib0315","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis","volume":"79","author":"Marissen","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101204_bib0320","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101204_bib0325","article-title":"In vivo efficacy of a cocktail of human monoclonal antibodies (CL184) against diverse North American bat rabies virus variants","volume":"2","author":"Franka","year":"2017","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0330","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1016\/j.vaccine.2008.08.050","article-title":"First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity","volume":"26","author":"Bakker","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2022.101204_bib0335","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0340","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00253-012-4171-4","article-title":"Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein","volume":"96","author":"Sun","year":"2012","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.coviro.2022.101204_bib0345","first-page":"393","article-title":"Generation of human ScFv antibodies for antigenic site III of rabies virus glycoprotein from antibody-phage libraries by chain shuffling","volume":"32","author":"Sun","year":"2016","journal-title":"Bing Du Xue Bao"},{"key":"10.1016\/j.coviro.2022.101204_bib0350","first-page":"399","article-title":"Development of recombinant human monoclonal antibody cocktail for post-exposure rabies prophylaxis","volume":"32","author":"Sun","year":"2016","journal-title":"Bing Du Xue Bao"},{"key":"10.1016\/j.coviro.2022.101204_bib0355","unstructured":"Website North China Pharmaceutical Group Corporation. http:\/\/www.ncpc.biz\/en\/news\/231.html. [Accessed 26 April 2021]."},{"key":"10.1016\/j.coviro.2022.101204_bib0360","unstructured":"Website Molecular Targeting Technologies, Inc. Development Pipeline. <http:\/\/www.mtarget.com\/PIPE.html>. [Accessed 26 April 2021]."},{"key":"10.1016\/j.coviro.2022.101204_bib0365","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101204_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2018.12.009","article-title":"Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses","volume":"35","author":"Du Pont","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2022.101204_bib0375","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1017\/cjn.2015.331","article-title":"Critical appraisal of the Milwaukee protocol for rabies: this failed approach should be abandoned","volume":"43","author":"Zeiler","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.coviro.2022.101204_sbref0380","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012628","article-title":"A combination of two human monoclonal antibodies cures symptomatic rabies","volume":"12","author":"de Melo","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.coviro.2022.101204_bib0385","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coviro.2022.101204_bib0390","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101204_bib0395","series-title":"Anti-SARS-CoV-2 Monoclonal Antibodies","year":"2021"},{"key":"10.1016\/j.coviro.2022.101204_bib0400","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3139","article-title":"Process and operations strategies to enable global access to antibody therapies","volume":"37","author":"Kelley","year":"2021","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.coviro.2022.101204_bib0405","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1126\/science.abe0773","article-title":"Advancing new tools for infectious diseases","volume":"370","author":"Gupta","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101204_bib0410","article-title":"Reassessing therapeutic antibodies for neglected and tropical diseases","volume":"14","author":"van Huijsduijnen","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2022.101204_bib0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106639","article-title":"Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives","volume":"85","author":"Parray","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coviro.2022.101204_bib0420","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","article-title":"Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection","volume":"588","author":"Bournazos","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101204_bib0425","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrd4478","article-title":"Bispecific antibodies rise again","volume":"13","author":"Garber","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coviro.2022.101204_bib0430","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1128\/jvi.64.6.3087-3090.1990","article-title":"Biological characterization of human monoclonal antibodies to rabies virus","volume":"64","author":"Dietzschold","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101204_bib0435","doi-asserted-by":"crossref","first-page":"W320","DOI":"10.1093\/nar\/gku316","article-title":"Deciphering key features in protein structures with the new ENDscript server","volume":"42","author":"Robert","year":"2014","journal-title":"Nucleic Acids Res"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722000116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722000116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:05:35Z","timestamp":1761818735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625722000116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":87,"alternative-id":["S1879625722000116"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101204","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101204"}}